Physician profile
Gregory S Hooks
NPI 1629037320
$6,791.09
in general payments reported to CMS, 2019-2025
42 companies · $1,918 in 2025
The $1,918 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,324 · 2020: $326 · 2022: $590 · 2023: $857 · 2024: $1,776 · 2025: $1,918.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,552.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,551.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $837.15 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $800.86 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $702.22 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $567.42 | 2019-2025 | |
| Abbvie INC. | $534.15 | 2022-2025 | |
| Amgen INC. | $499.75 | 2019-2025 | Otezla, Repatha, Otezla |
| Dexcom, INC. | $493.42 | 2023-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $297.50 | 2019-2025 | Jardiance |
| Exact Sciences Corporation | $172.87 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $170.98 | 2019-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $141.16 | 2019-2025 | |
| Xeris Pharmaceuticals, INC. | $130.61 | 2022-2024 | Gvoke Hypopen |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $110.97 | 2019-2025 | Xifaxan |
| Biohaven Pharmaceutical Holding Company LTD. | $104.44 | 2022 | |
| Edwards Lifesciences Corporation | $99.93 | 2022-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $91.78 | 2023-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Astellas Pharma US INC | $78.36 | 2019-2025 | Veozah |
| Dynavax Technologies Corporation | $72.87 | 2024-2025 | Heplisav-B |
| Shield Therapeutics INC | $71.91 | 2024-2025 | |
| Gilead Sciences, INC. | $67.90 | 2019-2020 | |
| Daiichi Sankyo INC. | $67.84 | 2022-2025 | Injectafer |
| Novartis Pharmaceuticals Corporation | $58.40 | 2022-2025 | |
| Amarin Pharma, INC. | $57.79 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $57.43 | 2025 | Gemtesa |
| Otsuka America Pharmaceutical, INC. | $56.84 | 2024-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $46.84 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $45.70 | 2024 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $41.38 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $34.91 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $34.40 | 2019-2025 | Gardasil 9, Capvaxive |
| Idorsia Pharmaceuticals US INC | $33.04 | 2023-2025 | Quviviq, Quviviq |
| Cvrx, INC. | $31.71 | 2024-2025 | Barostim Neo System |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.93 | 2025 | Caplyta |
| Inari Medical, INC. | $21.84 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Stryker Corporation | $19.04 | 2025 | Clottriever Bold Catheter |
| Allergan, INC. | $18.53 | 2019 | |
| Corcept Therapeutics | $16.75 | 2025 | Korlym |
| Upsher-Smith Laboratories LLC | $16.74 | 2019 | |
| Esperion Therapeutics, INC. | $16.45 | 2025 | Nexletol |
| Antares Pharma, INC. | $15.10 | 2019 | |
| Currax Pharmaceuticals LLC | $14.69 | 2022 | |
| Avanir Pharmaceuticals, INC. | $14.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Hooks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.